Novartis AG has been drawing attention as its stock remains around a 52-week high, enhanced by the planned radioligand plant in Florida. Despite a fall in share prices due to generics affecting their heart drug sales, overall performance has been promising and analysts are confident in Novartis's position in the market as a valuable hedge.
Morgan Stanley upgraded Novartis due to stock pullback and the launch of Rhapsido. Important announcements included the acquisition of US biotech firm
Avidity Biosciences in a $12 billion cash deal and the approval of Itsivma® by the US FDA. Nevertheless,
Goldman Sachs downgraded the Novartis stock to 'Sell' due to growth concerns. Adding favours to its run, Novartis's stock increased following reports of a potential White House pricing deal; this raised pre-market trading volumes. Novartis maintaining its position in the equity market is credited to a strong multi-year shareholder return and promising pipeline progress. Despite uncertainties from a generics bite, long-term value remains assured due to growth factors like a strong product pipeline, cash flow gains, and increased full-year guidance arising from acquisitions and portfolio growth.
Novartis Stocks News Analytics from Tue, 08 Jul 2025 07:00:00 GMT to Sat, 10 Jan 2026 19:36:00 GMT -
Rating 7
- Innovation 8
- Information 8
- Rumor 6
